Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2012
03/13/2012US8133959 Side-chain crystallizable polymers for medical applications
03/13/2012US8133921 Edible plant extract based insecticidal composition
03/13/2012US8133920 Growth hormone-containing formulation and method of use
03/13/2012US8133919 Dry fertilizer with growth hormone-containing formulation and methods of use and making
03/13/2012US8133918 Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
03/13/2012US8133917 Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform
03/13/2012US8133916 Control of milk production and mammary involution
03/13/2012US8133915 Interleukin-1 and tumor necrosis factor-α modulators; syntheses of such modulators and methods of using such modulators
03/13/2012US8133914 Compounds and compositions thereof
03/13/2012US8133913 Substituted indeno [1,2-b]indole derivatives as novel inhibitors of protein kinase CK2 and their use as tumor therapeutic agents, cytostatics and diagnostic aids
03/13/2012US8133912 Methyl aquocobyrinic acid derivative, alkylation composition, and method for detoxifying a harmful compound by utilizing the composition
03/13/2012US8133911 (R)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
03/13/2012US8133910 Thiophene derivatives as S1P1/EDGE1 receptor agonists
03/13/2012US8133909 Heteroaromatic monoamides as orexinin receptor antagonists
03/13/2012US8133908 Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine
03/13/2012US8133907 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin
03/13/2012US8133906 Method of treating amblyopia
03/13/2012US8133905 Biphenyl compounds useful as muscarinic receptor antagonists
03/13/2012US8133904 Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
03/13/2012US8133903 Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
03/13/2012US8133902 Ammosamides as anticancer agents
03/13/2012US8133901 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
03/13/2012US8133900 Use of bi-aryl meta-pyrimidine inhibitors of kinases
03/13/2012US8133899 Pyrrolo[2,3-d]pyrimidine compounds
03/13/2012US8133898 Renin inhibitors
03/13/2012US8133897 Phenylimidazole derivatives as PDE10A enzyme inhibitors
03/13/2012US8133896 Pyrimidine derivatives which are antagonist of the vitronectin receptor
03/13/2012US8133895 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
03/13/2012US8133894 N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones
03/13/2012US8133893 Trazodone and trazodone hydrochloride in purified form
03/13/2012US8133892 Compounds that are useful for improving pharmacokinetics
03/13/2012US8133891 Tricyclic anilide spirolactam CGRP receptor antagonists
03/13/2012US8133890 Glaucoma and/or ocular hypertension; stability; lower dosage
03/13/2012US8133889 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
03/13/2012US8133888 Hydrazide containing taxane conjugates
03/13/2012US8133887 Oxaphenanthrene derivatives
03/13/2012US8133886 Heterobicyclic carboxamides as inhibitors for kinases
03/13/2012US8133885 Non steroidal glucocorticoid receptor modulators
03/13/2012US8133884 Compounds for the treatment of hepatitis C
03/13/2012US8133883 Compositions containing piperacillin and tazobactam useful for injection
03/13/2012US8133882 Quinolone derivative or pharmaceutically acceptable salt thereof
03/13/2012US8133881 Carbohydrate conjugates to prevent abuse of controlled substances
03/13/2012US8133880 Purine derivatives and methods of use thereof
03/13/2012US8133879 Myocardial perfusion imaging methods and compositions
03/13/2012US8133878 Methods for treating restenosis
03/13/2012US8133877 Composition comprising an antisense sequence implicated in the regulation of angiogenesis
03/13/2012US8133876 Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
03/13/2012US8133874 Oligonucleotide or its functional homologue, a composition comprising the same and a method of treating B cell neoplasm
03/13/2012US8133872 Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes
03/13/2012US8133871 Dihydropseudoerythromycin derivatives
03/13/2012US8133870 Therapeutic furopyrimidines and thienopyrimidines
03/13/2012US8133869 And oxidized natural lignin phenols with a low molecular weigh; disinfecting, microbicidal, root growth enhancing activity
03/13/2012US8133868 Dipeptides for prevention of muscle breakdown and microbial infection
03/13/2012US8133866 Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
03/13/2012US8133861 Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
03/13/2012US8133857 NOTCH inhibition in the treatment of atherosclerosis
03/13/2012US8133681 Chemo-immunotherapy method
03/13/2012US8133515 Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
03/13/2012US8133507 Having desired release kinetics while providing drug abuse deterrence of reduced water and/or solvent extraction rate; formulation includes high viscosity liquid carrier and network former
03/13/2012US8133506 Drug delivery systems comprising weakly basic drugs and organic acids
03/13/2012US8133502 System for delivering a composition to the nasal membrane and method of using same
03/13/2012CA2685952C N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
03/13/2012CA2676670C Tricyclic compounds, compositions, and methods
03/13/2012CA2663175C Kinase inhibitor
03/13/2012CA2643097C Amine derivatives
03/13/2012CA2587791C Method for treating neuropathic pain and associated syndromes
03/13/2012CA2586871C Nonaqueous preparation for percutaneous absorption containing nonsteroidal anti-inflammatory analgesic
03/13/2012CA2586056C Aryloxy-substituted benzimidazole derivative
03/13/2012CA2586023C Aliphatic amine polymer salts for tableting
03/13/2012CA2565812C 4-phenylamino-quinazolin-6-yl-amides
03/13/2012CA2549824C Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
03/13/2012CA2548379C Compositions of galactomannan for the treatment of bowel diseases
03/13/2012CA2543452C Therapeutic agent for keratoconjunctival disorder
03/13/2012CA2540529C Means and methods for the recruitment and identification of stem cells
03/13/2012CA2536499C Buccal formulations of galanthamine and uses thereof
03/13/2012CA2530772C Composition and method for the treatment of water related ear disorders
03/13/2012CA2530444C Tricyclic .delta. opioid modulators
03/13/2012CA2524366C Benzothiazole derivatives as adenosine receptor ligands
03/13/2012CA2524344C Pyrazolo [4, 3-d]pyrimidines, process for their preparation and methods of use
03/13/2012CA2521254C Formulations for mediating inflammation and for reducing blood cholesterol
03/13/2012CA2515574C Aminophosphonic acid derivative, salt thereof, and modulator of s1p receptor
03/13/2012CA2514037C Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide
03/13/2012CA2512713C Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses
03/13/2012CA2511995C Pharmaceutical preparations for treatments of diseases and disorders of the breast
03/13/2012CA2509670C Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
03/13/2012CA2504697C Methods for treating migraine
03/13/2012CA2503212C Matieres pour filtres a eau et filtres a eau contenant un melange de particules de carbone microporeuses et mesoporeuses
03/13/2012CA2499878C Solid pharmaceutical formulations comprising telmisartan
03/13/2012CA2498207C Gel-stabilized nanoparticulate active agent compositions
03/13/2012CA2489227C Hla-a24-restricted cancer antigen peptides
03/13/2012CA2487648C Pharmaceutical preparations for oral administration, containing ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents
03/13/2012CA2486539C C-aryl glucoside sglt2 inhibitors and method
03/13/2012CA2480468C Fredericamycin derivatives
03/13/2012CA2467159C Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
03/13/2012CA2435126C Process
03/13/2012CA2419607C Peptidomimetic protease inhibitors
03/13/2012CA2407238C The use of thymosin alpha 1 to reduce the side effects of chemotherapy in cancer patients
03/13/2012CA2402191C Use of insulin for the treatment of cartilagenous disorders
03/13/2012CA2369074C Ether compounds, compositions, and uses thereof
03/13/2012CA2361806C Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
1 ... 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 ... 7860